In this pharmacokinetic and dose-escalation study of the carboplatin/paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) combination, patients were randomly assigned to receive paclitaxel either as a 1-hour or a 3-hour infusion. The 1-hour infusion was feasible, with maximum tolerated doses similar to those previously reported for a 3-hour infusion. Using patients' age, height, plasma creatinine, and plasma creatine kinase provided an improved estimate of the glomerular filtration rate compared with the more traditional creatinine-based formulas according to population analysis of data derived from glomerular filtration rate estimates performed by an isotope method. Studies of the p53 gene sequence of ovarian tumours at diagnosis suggest that p53 mutations are a potent predictor of response to subsequent treatment with carboplatin.
Calvert AH, Ghokul S, Al-Azraqi A, Wright J, Lind M, Bailey N, Highley M, Siddiqui N, Lunec J, Sinha D, Boddy A, Roberts T, Fenwick J. Carboplatin and paclitaxel, alone and in combination: dose escalation, measurement of renal function, and role of the p53 tumour suppressor gene. Seminars in Oncology 1999; 26; 90-94.
Professor E. David Williams, Sunderland Unit, Sunderland. Tel: +44 (0)191-569-9035.
Regional Medical Physics Department, Freeman Hospital, Newcastle upon Tyne, NE7 7DN, UK.
Tel: +44 (0)191-233-6161 E-mail: webmaster@rmpd.org.uk Web: http://www.rmpd.org.uk
By using this site you agree to our Terms and Conditions of Use. Please read our legal page.
Regional Medical Physics Department, a Clinical Directorate of the Newcastle upon Tyne Hospitals NHS Foundation Trust.
Copyright ©1999-2008 All Rights Reserved. Revised 7 November, 2008.
